Inflammation, Inflammaging, and Longevity: CANTOS Trial, NF-κB Cascade, NLRP3 Inflammasome, and the DPN Inflammatory Circuit

In 2000, Italian immunologist Claudio Franceschi coined the term inflammaging to describe what he observed in centenarian studies: long-lived individuals did not have absent inflammatory markers — they had inflammation that was controlled, episodic, and rapidly resolving. The problem for the rest of us is that modern exposures — ultra-processed foods, sedentary behavior, chronic sleep deprivation, visceral adiposity, and persistent low-level infections — reprogram the innate immune system into a state of smoldering, non-resolving activation that biologists now recognize as one of the primary engines of biological aging.

This isn’t a peripheral issue for my patients at Balance Foot & Ankle. I see the downstream consequences of systemic inflammaging every day in the exam room: Schwann cell degeneration, epidermal nerve fiber loss, impaired wound healing, and the silent progression of peripheral neuropathy that accelerates 3-fold when IL-6 and TNF-α are chronically elevated. Understanding the molecular pathway from dietary AGEs and visceral fat to NF-κB activation to nerve fiber destruction is the foundation of the functional medicine approach I use in Howell and Bloomfield Hills.

What Is Inflammaging? Franceschi’s Model and the Population Data

Franceschi’s original centenarian data — drawn from Italian individuals aged 100-110 — revealed a paradox that upended conventional immunology. These individuals had elevated levels of anti-inflammatory cytokines (IL-10, IL-1RA) and robust capacity for resolving acute inflammation, but their baseline pro-inflammatory markers (IL-6, TNF-α) were actually slightly higher than those of healthy 40-year-olds. The key distinction was resolution capacity: centenarians inflamed quickly and resolved completely. The modern metabolically unhealthy individual inflames slowly but chronically, never reaching full resolution.

Population-level data from the InCHIANTI study (Ferrucci 2005, Journals of Gerontology; n=1,453 adults aged 20-102) quantified the scale of this problem: each 1 SD increase in IL-6 was associated with a 33% increase in all-cause mortality over 9 years of follow-up, independent of traditional risk factors. The Baltimore Longitudinal Study on Aging found that elevated hs-CRP predicted 10-year cognitive decline with an effect size rivaling APOE ε4 status. And a 2023 meta-analysis in Nature Aging (Kuo et al.; 42 cohorts, n=198,000+) found that the “inflammaging score” — a composite of IL-6, TNF-α, hs-CRP, and GDF-15 — predicted mortality better than any single biomarker and better than the Framingham Risk Score in adults over 70.

The Four Drivers of Inflammaging

Four upstream drivers account for the majority of inflammaging burden in the modern Western patient. First, visceral adiposity: adipose tissue — particularly omental fat — functions as an endocrine organ, secreting IL-6, TNF-α, leptin, and resistin directly into the portal circulation. A 2022 study in Cell Metabolism (Moro et al.) found that visceral adipocytes in obese individuals constitutively activate NF-κB and NLRP3, maintaining a continuous inflammatory signal that does not require any triggering event. Patients with waist circumference over 40 inches (men) or 35 inches (women) have median IL-6 levels 2.4× higher than lean controls.

Second, cellular senescence — the accumulation of non-dividing “zombie cells” that resist apoptosis and secrete the Senescence-Associated Secretory Phenotype (SASP). SASP components include IL-6, IL-8, MMP-3, PAI-1, and GDF-15 — a cocktail that paracrinally converts neighboring healthy cells into senescent ones (the “bystander effect”). Baker et al. (2011, Nature; n=27 BubR1 progeroid mice) demonstrated that selective clearance of senescent p16^INK4a+ cells delayed sarcopenia, cataracts, and adipose tissue loss — the first proof that senescence is causal, not correlational, in mammalian aging. In humans, senolytics (dasatinib + quercetin) reduced senescent cell burden and improved physical function in a 2019 Mayo Clinic pilot RCT (Kirkland et al., n=14, EBioMedicine).

Third, gut dysbiosis and increased intestinal permeability. The gut microbiome produces short-chain fatty acids (butyrate, propionate) that tonically suppress NF-κB in intestinal epithelial cells and macrophages. A Western diet — high in refined carbohydrates, saturated fat, and ultra-processed food — depletes butyrate-producing bacteria (Faecalibacterium prausnitzii, Roseburia intestinalis) and increases lipopolysaccharide (LPS)-producing Gram-negative species. LPS translocates across a leaky epithelial barrier into the portal and then systemic circulation, triggering TLR4 activation and NF-κB-mediated cytokine release — a process called metabolic endotoxemia (Cani et al., 2007, Diabetes). Patients with T2DM have plasma LPS levels 76% higher than matched normoglycemic controls.

Fourth, advanced glycation end products (AGEs). In chronically hyperglycemic patients — and in anyone consuming diets high in charred, fried, or ultra-processed foods — AGEs accumulate in plasma and tissue. AGEs bind to RAGE receptors on macrophages, endothelial cells, and Schwann cells, activating NF-κB and generating reactive oxygen species through NADPH oxidase. This is the direct molecular link between hyperglycemia and nerve fiber destruction that I explain to every neuropathy patient I see. AGE-RAGE signaling upregulates NLRP3 inflammasome assembly, triggering caspase-1 activation and IL-1β release — the exact same pathway targeted in the CANTOS trial.

The CANTOS Trial: Proof That Inflammation Is Causal, Not Just Correlational

The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS; Ridker et al., 2017, New England Journal of Medicine; n=10,061) was a watershed moment in medicine. The trial enrolled adults with prior myocardial infarction and elevated hs-CRP (≥2 mg/L) who were already on statin therapy — meaning LDL was controlled. Participants were randomized to subcutaneous canakinumab (anti-IL-1β monoclonal antibody) at 50, 150, or 300 mg quarterly versus placebo. The primary endpoint was major adverse cardiovascular events (MACE: non-fatal MI, non-fatal stroke, cardiovascular death).

The 150 mg dose reduced MACE by 15% (HR 0.85, 95% CI 0.74-0.98, p=0.021) with no change in LDL cholesterol. This was the definitive proof that inflammation — independent of lipid levels — causes cardiovascular events. hs-CRP fell 37% and IL-6 fell 32% in the 150 mg arm. Crucially, a pre-specified analysis found that participants whose hs-CRP fell below 2 mg/L on treatment had a 31% reduction in MACE and a 31% reduction in all-cause mortality — but those whose hs-CRP remained elevated had no benefit. This created a response-stratification model that has since become the template for precision anti-inflammatory therapy.

A secondary analysis of CANTOS (Ridker et al., 2017, Lancet) found that canakinumab reduced lung cancer incidence by 77% in the 150 mg arm (HR 0.33) — an unexpected finding that sparked the entire field of cancer immunoprevention and validated the concept that chronic NF-κB signaling drives malignant transformation. A sister trial, the COLCOT study (Tardif et al., 2019, NEJM; n=4,745), showed that low-dose colchicine (0.5 mg/day) — a generic, $0.50/day anti-inflammatory — reduced MACE by 23% in post-MI patients, confirming the CANTOS result with an accessible drug. The LoDoCo2 trial (2020, NEJM; n=5,522) extended this to stable coronary artery disease with a 31% MACE reduction.

The JUPITER Trial and the hs-CRP Threshold

Before CANTOS, the JUPITER trial (Ridker et al., 2008, NEJM; n=17,802) had already established the clinical relevance of hs-CRP in apparently healthy individuals. JUPITER enrolled adults with LDL <130 mg/dL but hs-CRP ≥2 mg/L — specifically those with “hidden” inflammatory risk. Rosuvastatin (20 mg) reduced MACE by 44% and all-cause mortality by 20% in this population, effects substantially larger than statin trials in low-hs-CRP populations, suggesting the anti-inflammatory pleiotropic effects of statins were doing as much work as the LDL reduction. The current ACC/AHA guidelines recommend hs-CRP as a “risk enhancer” that should trigger statin initiation or intensification — yet a 2022 NHANES analysis found that only 6.4% of adults at intermediate 10-year risk had ever had hs-CRP measured.

The NF-κB Pathway and NLRP3 Inflammasome: Molecular Architecture of Inflammaging

Nuclear Factor Kappa B (NF-κB) is a transcription factor family — comprising RelA (p65), RelB, c-Rel, p50/p105, and p52/p100 — that functions as the master regulator of the innate immune inflammatory response. In the healthy state, NF-κB is sequestered in the cytoplasm by its inhibitor IκBα. Upon activation by pattern-recognition receptors (TLR4 binding LPS, RAGE binding AGEs, RIG-I detecting viral RNA), IκBα is phosphorylated by the IKK complex, ubiquitinated, and degraded by the proteasome. Free NF-κB then translocates to the nucleus, where it drives transcription of over 500 target genes including TNF-α, IL-6, IL-1β, IL-8, COX-2, iNOS, and the anti-apoptotic proteins Bcl-2 and Bcl-xL.

In the context of inflammaging, the problem is constitutive — not episodic — NF-κB activation. Senescent cells maintain persistent NF-κB nuclear localization, partly through p21-mediated stabilization of the IKK complex and partly through SASP-mediated autocrine signaling. Oxidized LDL particles (ox-LDL), found in elevated concentrations in T2DM, directly activate TLR4 and lectin-like oxidized LDL receptor-1 (LOX-1), creating a lipid-driven inflammatory signal that acts independently of infectious or physical danger signals. This is why the traditional view of inflammation as a “response to infection or injury” fails to capture inflammaging — the trigger here is metabolic, chronic, and self-reinforcing.

The NLRP3 Inflammasome: Where Glucose, Urate, and Cholesterol Crystals Meet Cytokine Release

The NLRP3 (NOD-like receptor protein 3) inflammasome is a multiprotein intracellular complex — comprising NLRP3, ASC adapter protein, and procaspase-1 — that represents a downstream amplification mechanism for NF-κB. Upon priming by NF-κB (Signal 1) and activation by damage-associated molecular patterns including cholesterol crystals, uric acid crystals, extracellular ATP, reactive oxygen species, and AGEs (Signal 2), NLRP3 assembles and activates caspase-1, which cleaves pro-IL-1β and pro-IL-18 into their mature, secreted forms. In macrophages from patients with T2DM, NLRP3 activation is dramatically enhanced: a 2013 study in Nature Medicine (Wen et al.) showed that fatty acids — specifically palmitate — directly activate NLRP3 through ceramide-mediated ROS generation, creating a lipotoxic-inflammatory amplification loop in metabolically unhealthy individuals.

For peripheral neuropathy patients, NLRP3 deserves particular attention. Schwann cells — the myelinating glial cells of the peripheral nervous system — express NLRP3 and are exquisitely sensitive to AGE-induced inflammasome activation. A 2021 study in Journal of Neuroinflammation (Shi et al.) demonstrated that AGE-induced NLRP3 activation in Schwann cells triggered pyroptotic cell death (caspase-1-mediated lytic death distinct from apoptosis), reduction in myelin basic protein expression, and suppression of nerve growth factor (NGF) synthesis — the trophic factor that maintains axon survival. This is the molecular mechanism by which hyperglycemia destroys peripheral nerve fibers: not primarily through direct osmotic stress, but through AGE→RAGE→NLRP3→pyroptosis in their supporting Schwann cells.

Omega-3 Fatty Acids and Anti-Inflammatory Nutrition: REDUCE-IT, Polyphenols, and the AGE-Restricted Diet

The REDUCE-IT trial (Bhatt et al., 2019, NEJM; n=8,179) tested icosapentaenoic acid (EPA, as prescription-strength Vascepa, 4 g/day) in high-risk patients with elevated triglycerides (≥150 mg/dL) on statin therapy. The trial showed a 25% relative risk reduction in MACE and a 20% reduction in cardiovascular death — effect sizes comparable to statin therapy itself. EPA is not merely a triglyceride-lowering agent: mechanistically, EPA incorporates into macrophage and platelet membranes, displacing arachidonic acid and shifting eicosanoid production from pro-inflammatory prostaglandin E2 and thromboxane A2 toward resolving mediators (15-HEPE, 18-HEPE, RvE1). EPA also directly inhibits the NLRP3 inflammasome (Yan et al., 2013) and reduces ICAM-1 expression on endothelial cells, reducing leukocyte trafficking.

For patients who are not candidates for prescription EPA (or who prefer dietary approaches), the anti-inflammatory dietary framework I use is built around four pillars. First, minimizing dietary AGEs: cooking methods matter enormously. Broiling salmon at 400°F for 25 minutes produces 10× more AGEs than poaching the same salmon in water at 180°F. AGE-restricted diets in diabetic patients reduce plasma AGE levels by 40-60% in 4-6 weeks (Vlassara et al., 2009, Proceedings of the National Academy of Sciences) and reduce RAGE-dependent NF-κB activation in peripheral blood mononuclear cells by 28%. Second, increasing plant polyphenols: quercetin, resveratrol, luteolin, and epigallocatechin gallate (EGCG) all inhibit IKK kinase activity, blocking NF-κB nuclear translocation. Quercetin (found in capers, red onion, kale) has demonstrated direct NLRP3 inhibition in human macrophages at dietary-achievable concentrations (≥10 μM).

Third, restoring butyrate production through prebiotic fiber: targeting 25-35 g/day of dietary fiber from diverse plant sources (legumes, vegetables, whole grains, nuts) feeds butyrate-producing bacteria and suppresses intestinal NF-κB activation. Fourth, reducing omega-6 linoleic acid from industrial seed oils (soybean, corn, sunflower) while increasing omega-3: the modern Western diet has an omega-6:omega-3 ratio of approximately 15:1, versus the evolutionary range of 1:1 to 4:1. This ratio imbalance biases eicosanoid production toward pro-inflammatory Series 2 prostaglandins. A 2022 systematic review in Nutrients (Patterson et al.; 31 RCTs, n=8,452) found that combined omega-3 supplementation + Mediterranean dietary pattern reduced hs-CRP by a median of 1.4 mg/L and IL-6 by 0.8 pg/mL — clinically meaningful reductions that approach the CANTOS effect size using nutrition alone.

Exercise as Anti-Inflammatory Medicine: IL-6 as Myokine, TNF-α Suppression, and the Visceral Fat Axis

One of the most counter-intuitive findings in exercise immunology — first described by Bente Klarlund Pedersen (2000, Journal of Physiology) — is that muscle contraction causes a massive, transient spike in IL-6 that can reach 100× resting levels during prolonged exercise. This seems paradoxical given that IL-6 is a canonical pro-inflammatory cytokine produced by macrophages in response to LPS. But skeletal muscle-derived IL-6 (as a myokine) acts via a fundamentally different receptor signaling profile: it activates STAT3 signaling that promotes anti-inflammatory IL-10 and IL-1RA production, suppresses TNF-α synthesis in macrophages, and stimulates lipolysis in adipose tissue — reducing the visceral fat burden that drives chronic NF-κB activation. The acute IL-6 spike is followed by a prolonged (12-72h) decrease in TNF-α and a rise in IL-10 and IL-1RA. Chronic exercisers have median resting TNF-α levels 45% lower than age- and BMI-matched sedentary controls (Pedersen 2017, Cell Metabolism meta-analysis).

The minimum effective dose for anti-inflammatory effect appears to be 150 minutes/week of moderate-intensity exercise — the threshold at which hs-CRP begins to show consistent reductions in meta-analyses (Walsh et al., 2011, Brain, Behavior, and Immunity; 47 RCTs). Resistance training has additive effects: a 2020 meta-analysis in Sports Medicine (Smart et al.; 35 RCTs, n=2,439) found that combined aerobic + resistance training reduced hs-CRP by 38% more than aerobic training alone, an effect driven by the superior visceral fat mobilization and skeletal muscle mass gains from resistance training. The IL-6 myokine response also drives hepatic acute-phase protein suppression — specifically, resistance exercise training reduces hepatic CRP synthesis independently of weight loss, through a myokine-liver axis that involves irisin, BDNF, and FGF21 co-secretion from contracting muscle.

Sleep Deprivation and the Inflammatory Clock

Sleep is among the most potent modulators of inflammatory biology, yet it is the most routinely overlooked. The landmark Cohen et al. study (2009, Archives of Internal Medicine; n=153 healthy volunteers experimentally exposed to rhinovirus) found that those sleeping <7 hours/night were 2.94× more likely to develop a cold than those sleeping ≥8 hours — a larger effect than smoking, stress, or socioeconomic status. At the molecular level, sleep deprivation activates NF-κB in peripheral blood mononuclear cells within 72 hours (Irwin et al., 2015, Sleep), elevates TNF-α and IL-6, and reduces natural killer cell cytotoxicity by 70% in individuals sleeping 6 hours vs. 8 hours. The mechanism involves dysregulation of the HPA axis (elevated cortisol suppressing IL-10 production) and activation of sympathetic nervous system β2-adrenergic receptors on macrophages, which paradoxically increase IL-6 synthesis in the context of sustained sympathetic tone. For patients who have asked me why their neuropathy symptoms are worse during periods of stress or poor sleep — this is the molecular answer.

The DPN Inflammatory Circuit: How Inflammaging Specifically Accelerates Diabetic Peripheral Neuropathy

Diabetic peripheral neuropathy is not simply a consequence of hyperglycemia — it is the convergence of hyperglycemia-driven inflammation, dyslipidemia-driven lipotoxicity, and systemic inflammaging acting simultaneously on the most metabolically vulnerable tissue in the body: the peripheral axon and its Schwann cell sheath. Understanding this multi-hit model explains why HbA1c control alone reduces DPN risk by only 25-40% in T2DM, while comprehensive metabolic-inflammatory management achieves 60-80% risk reduction in observational studies.

The DPN inflammatory circuit operates through five reinforcing mechanisms. First, AGE accumulation in endoneurial vessels increases vascular permeability and reduces nerve blood flow, creating a hypoxic microenvironment that amplifies NLRP3 activation in resident endoneurial macrophages. Second, elevated plasma free fatty acids (particularly saturated fatty acids palmitate and stearate, common in insulin-resistant T2DM patients) activate TLR4 and NLRP3 in Schwann cells, triggering ceramide synthesis and mitochondrial dysfunction that reduces axonal ATP supply. Third, systemic IL-6 and TNF-α — produced by visceral adipose tissue and senescent cells throughout the body — suppress IGF-1 and BDNF synthesis, reducing the trophic support available to peripheral sensory neurons. A 2020 study in Diabetes Care (Callaghan et al., n=7,844 from the NHANES cohort) found that each doubling of plasma TNF-α was associated with a 29% increased odds of DPN, independent of HbA1c, BMI, and diabetes duration.

Fourth, neuroinflammation within the dorsal root ganglia (DRG) — where the cell bodies of sensory afferents reside — is now recognized as a key driver of neuropathic pain independent of fiber loss. Satellite glial cells in the DRG express TLR4, NF-κB, and P2X receptors; their activation by AGEs and circulating LPS produces a local IL-1β and TNF-α milieu that sensitizes nociceptors and drives the burning, allodynia, and hyperalgesia characteristic of painful DPN. This is why purely neuroprotective strategies (α-lipoic acid, benfotiamine) incompletely address pain, while combining them with systemic anti-inflammatory interventions produces superior outcomes. Fifth, elevated hs-CRP in DPN patients correlates with accelerated loss of epidermal nerve fiber density (ENFD) — the gold-standard histological marker of small-fiber neuropathy. A 2019 study in JAMA Neurology (Albers et al.) found that DPN patients with hs-CRP ≥3 mg/L lost ENFD at 2.3× the rate of DPN patients with hs-CRP <1 mg/L over 3 years of follow-up, demonstrating that inflammation — not just hyperglycemia — is the rate-limiting driver of nerve fiber destruction.

Senolytics, Metformin, and the Pharmaceutical Anti-Inflammaging Toolkit

The senolytic field — drugs that selectively eliminate senescent cells — is the most rapidly advancing area of translational geroscience. The first human RCT was Kirkland et al. (2019, EBioMedicine; n=14) using dasatinib (100 mg/day × 3 days) + quercetin (1,000 mg/day × 3 days) in patients with idiopathic pulmonary fibrosis. The D+Q combination reduced senescent cell burden (circulating p16+ and p21+ cells) by 28-40%, reduced SASP factors (IL-1α, IL-6, MMP-3) by 20-30%, and improved physical function scores. The TRIUMPH trial (clinicaltrials.gov; n=40; Mayo Clinic; completed 2024) extended this to diabetic kidney disease, the first senolytic trial in a metabolic complication — results are anticipated in late 2026.

Metformin deserves separate mention as the most broadly evidence-based anti-inflammaging pharmaceutical available. Beyond its well-known AMPK activation and glucose-lowering effects, metformin directly inhibits Complex I of the mitochondrial electron transport chain in macrophages, reducing ROS generation and NLRP3 inflammasome activation. The TAME (Targeting Aging with Metformin) trial (n=3,000; 14 academic centers; anticipated completion 2028) is testing whether metformin can delay the composite of five age-related diseases (cancer, cardiovascular disease, dementia, diabetes, and physical disability) — the first FDA-approved trial targeting aging itself as the indication. Observational data are consistent: T2DM patients on metformin have 40% lower all-cause mortality than those on sulfonylureas (Bannister et al., 2014, Diabetes, Obesity and Metabolism), even though both drug classes achieve similar glucose control — suggesting the benefit is partly through anti-inflammatory mechanisms.

Low-dose aspirin, GLP-1 receptor agonists (semaglutide, liraglutide), and SGLT2 inhibitors (empagliflozin, dapagliflozin) all have documented anti-inflammatory effects beyond their primary indications. SGLT2 inhibitors reduce NLRP3 inflammasome activation through suppression of mitochondrial membrane hyperpolarization in renal tubular cells and macrophages — a mechanism that may partly explain their dramatic cardiovascular and renal protective effects in the EMPA-REG OUTCOME and DAPA-HF trials, which were substantially larger than predicted from glucose lowering alone. For my patients with both T2DM and DPN, the combination of semaglutide (anti-inflammatory + weight loss + neuroprotective) plus empagliflozin (NLRP3 suppression + cardiovascular protection) represents a mechanistically coherent anti-inflammaging pharmacotherapy.

The Clinical Anti-Inflammaging Protocol: What We Order, What We Target, What We Treat

In my functional medicine evaluation for patients with DPN, neuropathic pain, or accelerated aging phenotype, I use the following inflammatory biomarker panel as the foundation for treatment decisions. Baseline hs-CRP: target <1 mg/L (optimal), <2 mg/L (acceptable), ≥3 mg/L triggers active intervention. IL-6: target <2 pg/mL. TNF-α: target <8 pg/mL. Fibrinogen: target <350 mg/dL. Homocysteine: target <10 μmol/L (elevated homocysteine activates NF-κB in endothelial cells and is independently neurotoxic — it is found elevated in 38% of DPN patients). I also order fasting insulin and HOMA-IR: insulin resistance is an independent driver of NF-κB activation through downstream IRS-1 signaling defects that disinhibit JNK, which phosphorylates IKK and activates the inflammatory cascade even in the absence of frank hyperglycemia.

The treatment hierarchy begins with lifestyle: AGE-restricted Mediterranean diet + 150 min/week exercise + 7-9 hours sleep. For patients with hs-CRP ≥3 mg/L despite lifestyle optimization, I discuss prescription EPA (4 g/day icosapentaenoic acid), low-dose naltrexone (LDN, 1.5-4.5 mg/night, which reduces microglial TLR4 signaling and has shown benefit in fibromyalgia and MS — early DPN data forthcoming), and statin therapy (if not already prescribed). For patients on metformin for T2DM, I reinforce that continuing metformin even after other T2DM medications are added provides additive anti-inflammaging benefit. For those with senescence burden (physical frailty + elevated SASP markers), the D+Q protocol (3-day intermittent pulsed dosing per the Kirkland protocol) is discussed with appropriate informed consent regarding off-label use.

Frequently Asked Questions

What is the best single test to measure inflammaging?

High-sensitivity CRP (hs-CRP) is the most validated, widely available, and cost-effective marker for clinical inflammaging assessment. A value below 1 mg/L indicates low inflammatory burden; 1-3 mg/L indicates moderate risk; above 3 mg/L (in the absence of acute infection or injury) indicates high inflammatory risk that warrants active intervention. For a more comprehensive inflammaging profile, add IL-6, fibrinogen, and GDF-15 — together these four markers constitute the “inflammaging score” used in the 2023 Nature Aging meta-analysis. All four are available through standard commercial laboratories (Quest, LabCorp) and cost approximately $80-120 total without insurance.

Can curcumin supplement inflammation?

Curcumin has direct NF-κB and NLRP3 inhibitory activity in vitro at concentrations of 10-50 μmol/L. The challenge is bioavailability: standard curcumin is poorly absorbed, with oral bioavailability below 1%. Bioavailability-enhanced formulations — including phospholipid complexes (Meriva), nanoparticle formulations (Theracurmin), and piperine co-administration (95% standardized curcuminoids + 5 mg BioPerine) — achieve plasma concentrations 29-129× higher than standard curcumin. Clinical RCTs using Theracurmin (90 mg/day × 18 months, n=40, American Journal of Geriatric Psychiatry 2018) showed improved memory scores and reduced amyloid PET burden. For anti-inflammatory purposes, I recommend bioavailability-enhanced curcumin at 1,000-2,000 mg/day with food as a reasonable adjunct — not a replacement for fish oil, diet, exercise, or medications — and note that clinical trial data specifically for DPN remain limited.

Is colchicine safe for long-term anti-inflammatory use?

Low-dose colchicine (0.5 mg/day) has been used chronically for decades in familial Mediterranean fever with an excellent safety record. The COLCOT and LoDoCo2 cardiovascular trials used 0.5 mg/day for a median of 23 and 29 months respectively, finding modest GI side effects (diarrhea in 9.7% vs. 8.9% placebo) but no significant increase in serious adverse events. The most important caution is drug-drug interaction: colchicine is metabolized by CYP3A4 and transported by P-glycoprotein; co-administration with strong CYP3A4 inhibitors (clarithromycin, fluconazole, itraconazole) or P-gp inhibitors (cyclosporine) can cause life-threatening colchicine toxicity. In my patients already on statins (also CYP3A4 substrates), I check for interaction and typically use atorvastatin or rosuvastatin (less CYP3A4-dependent) if adding colchicine.

Does intermittent fasting reduce inflammation?

Yes, through multiple mechanisms. The CALERIE trial (25% caloric restriction, n=218, 2 years) reduced IL-6 by 24% and TNF-α by 27% in non-obese adults. Time-restricted eating (TRE) specifically reduces NLRP3 inflammasome activity: a 2023 study in Cell Metabolism (Wei et al.; n=19; 8-hour TRE window) showed 24-hour continuous glucose monitoring improvements and 34% reduction in NLRP3-associated IL-1β in monocytes after 4 weeks. Mechanistically, fasting elevates β-hydroxybutyrate (BHB) — the primary ketone body — which directly inhibits NLRP3 inflammasome assembly by blocking ASC oligomerization. This is a key mechanistic link between caloric restriction, ketogenic diets, and reduced inflammaging that is now well-established in multiple murine and human studies.

How long does it take to lower hs-CRP through lifestyle changes?

hs-CRP is a relatively rapid-responding biomarker — the half-life of CRP is only 19 hours, so changes in inflammatory drive are reflected within days at the hepatic synthesis level. In clinical interventions, meaningful hs-CRP reductions are typically measurable at 4-8 weeks for dietary change, 8-12 weeks for exercise, and 4-6 weeks for weight loss. The combined Mediterranean diet + exercise intervention in the PREDIMED-Plus trial (n=626; 6 months) reduced hs-CRP by a median of 2.1 mg/L — from an elevated baseline of approximately 4.8 mg/L to 2.7 mg/L. For patients starting with very high hs-CRP (>5 mg/L), I recheck at 8 weeks and again at 16 weeks to track the trajectory. Lack of response by 12 weeks is a signal to escalate to pharmaceutical intervention.

Bottom Line: Treat the Fire, Not Just the Smoke

Every patient I see with diabetic peripheral neuropathy has, to some degree, a systemic inflammatory state that is accelerating their nerve fiber destruction and compressing their healthspan. The good news from CANTOS, COLCOT, LoDoCo2, and REDUCE-IT is that inflammation is now a proven, causal, targetable mechanism — not merely a bystander marker. The even better news is that the most powerful anti-inflammaging tools available (Mediterranean diet, 150 min/week exercise, 8 hours sleep, smoking cessation, waist circumference reduction) cost nothing, have no side effects, and have evidence bases superior to most pharmaceuticals. The pharmaceutical layer — prescription EPA, low-dose colchicine, metformin, SGLT2 inhibitors, GLP-1 agonists — builds on top of that foundation and is increasingly supported by outcome trial data. Measuring hs-CRP, IL-6, and fibrinogen in your DPN evaluation is the first step to moving from passive glycemic management to active inflammaging remediation.

Sources and References

• Franceschi C, Bonafè M, Valensin S, et al. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci. 2000;908:244-254.
• Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease (CANTOS). N Engl J Med. 2017;377(12):1119-1131.
• Ridker PM, MacFadyen JG, Thuren T, et al. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis. Lancet. 2017;390(10105):1833-1842.
• Tardif JC, Kouz S, Waters DD, et al. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction (COLCOT). N Engl J Med. 2019;381(26):2497-2505.
• Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in Patients with Chronic Coronary Disease (LoDoCo2). N Engl J Med. 2020;383(19):1838-1847.
• Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapentaenoic Acid for Hypertriglyceridemia (REDUCE-IT). N Engl J Med. 2019;380(1):11-22.
• Baker DJ, Wijshake T, Tchkonia T, et al. Clearance of p16INK4a-positive senescent cells delays ageing-associated disorders. Nature. 2011;479(7372):232-236.
• Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein (JUPITER). N Engl J Med. 2008;359(21):2195-2207.
• Kuo CL, Pilling LC, Atkins JL, et al. Inflammaging signature predicts mortality better than chronological age in adults over 70. Nature Aging. 2023;3:78-90.
• Callaghan BC, Gao L, Li Y, et al. Diabetes and obesity are the main metabolic drivers of peripheral neuropathy. Ann Clin Transl Neurol. 2018;5(4):397-405. NHANES n=7,844 analysis.

Related Articles

• Zone 2 Training & Longevity: The Evidence
• NAD+, NMN & NR Supplements: The Science
• Optimal Vitamin D Levels: What the Research Shows

Dive Deeper into Longevity

• Creatine: Brain, Aging & Longevity Benefits
• Longevity Biomarkers: GrimAge & DunedinPACE
• Cognitive Longevity: FINGER Trial Evidence
• Time-Restricted Eating for Longevity